Budesonide/formoterol pMDI
Sponsors
AstraZeneca
Conditions
AsthmaChronic Obstructive Pulmonary Disease
Phase 3
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
CompletedNCT00206154
Start: 2005-04-30End: 2006-12-31Target: 1500Updated: 2009-03-27
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
CompletedNCT00206167
Start: 2005-04-30End: 2007-09-30Target: 1600Updated: 2009-03-27
A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects
CompletedNCT00449527
Start: 2007-03-31End: 2007-08-31Updated: 2011-01-24
A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects
CompletedNCT00449501
Start: 2007-03-31End: 2007-11-30Updated: 2011-01-24